Telomerase Treatment Prevents Lung Profibrotic Pathologies Associated with Physiological Aging

Overview

Journal J Cell Biol

Specialty Cell Biology

Date 2020 Aug 11

PMID 32777016

Citations 29

Authors

Sergio Pineiro-Hermida

Chiara Autilio

Paula Martinez

Fatima Bosch

Jesus Perez-Gil

Maria A Blasco

Affiliations

Soon will be listed here.

Abstract

Short/dysfunctional telomeres are at the origin of idiopathic pulmonary fibrosis (IPF) in patients mutant for telomere maintenance genes. However, it remains unknown whether physiological aging leads to short telomeres in the lung, thus leading to IPF with aging. Here, we find that physiological aging in wild-type mice leads to telomere shortening and a reduced proliferative potential of alveolar type II cells and club cells, increased cellular senescence and DNA damage, increased fibroblast activation and collagen deposits, and impaired lung biophysics, suggestive of a fibrosis-like pathology. Treatment of both wild-type and telomerase-deficient mice with telomerase gene therapy prevented the onset of lung profibrotic pathologies. These findings suggest that short telomeres associated with physiological aging are at the origin of IPF and that a potential treatment for IPF based on telomerase activation would be of interest not only for patients with telomerase mutations but also for sporadic cases of IPF associated with physiological aging.

Citing Articles

Telomere function and regulation from mouse models to human ageing and disease.

Jones-Weinert C, Mainz L, Karlseder J Nat Rev Mol Cell Biol. 2024; .

PMID: 39614014 DOI: 10.1038/s41580-024-00800-5.

Guidelines for minimal information on cellular senescence experimentation in vivo.

Ogrodnik M, Carlos Acosta J, Adams P, dAdda di Fagagna F, Baker D, Bishop C Cell. 2024; 187(16):4150-4175.

PMID: 39121846 PMC: 11790242. DOI: 10.1016/j.cell.2024.05.059.

Gene Therapy for Skin Aging.

Saad F Curr Gene Ther. 2024; 25(1):2-9.

PMID: 38529607 DOI: 10.2174/0115665232286489240320051925.

mTert induction in p21-positive cells counteracts capillary rarefaction and pulmonary emphysema.

Lipskaia L, Breau M, Cayrou C, Churikov D, Braud L, Jacquet J EMBO Rep. 2024; 25(3):1650-1684.

PMID: 38424230 PMC: 10933469. DOI: 10.1038/s44319-023-00041-1.

Alveolar Organoids in Lung Disease Modeling.

Purev E, Bahmed K, Kosmider B Biomolecules. 2024; 14(1).

PMID: 38254715 PMC: 10813493. DOI: 10.3390/biom14010115.

References

Lopez-Otin C, Blasco M, Partridge L, Serrano M, Kroemer G . The hallmarks of aging. Cell. 2013; 153(6):1194-217. PMC: 3836174. DOI: 10.1016/j.cell.2013.05.039. View

Acosta J, OLoghlen A, Banito A, Guijarro M, Augert A, Raguz S . Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell. 2008; 133(6):1006-18. DOI: 10.1016/j.cell.2008.03.038. View

Ahluwalia N, Shea B, Tager A . New therapeutic targets in idiopathic pulmonary fibrosis. Aiming to rein in runaway wound-healing responses. Am J Respir Crit Care Med. 2014; 190(8):867-78. PMC: 4299574. DOI: 10.1164/rccm.201403-0509PP. View

Karimi-Shah B, Chowdhury B . Forced vital capacity in idiopathic pulmonary fibrosis--FDA review of pirfenidone and nintedanib. N Engl J Med. 2015; 372(13):1189-91. DOI: 10.1056/NEJMp1500526. View

Blasco M . Mice with bad ends: mouse models for the study of telomeres and telomerase in cancer and aging. EMBO J. 2005; 24(6):1095-103. PMC: 556402. DOI: 10.1038/sj.emboj.7600598. View

Jakubzick C, Choi E, Joshi B, Keane M, Kunkel S, Puri R . Therapeutic attenuation of pulmonary fibrosis via targeting of IL-4- and IL-13-responsive cells. J Immunol. 2003; 171(5):2684-93. DOI: 10.4049/jimmunol.171.5.2684. View

Meiners S, Eickelberg O, Konigshoff M . Hallmarks of the ageing lung. Eur Respir J. 2015; 45(3):807-27. DOI: 10.1183/09031936.00186914. View

Herrera E, Samper E, Blasco M . Telomere shortening in mTR-/- embryos is associated with failure to close the neural tube. EMBO J. 1999; 18(5):1172-81. PMC: 1171208. DOI: 10.1093/emboj/18.5.1172. View

Rawlins E, Okubo T, Xue Y, Brass D, Auten R, Hasegawa H . The role of Scgb1a1+ Clara cells in the long-term maintenance and repair of lung airway, but not alveolar, epithelium. Cell Stem Cell. 2009; 4(6):525-34. PMC: 2730729. DOI: 10.1016/j.stem.2009.04.002. View

10.

Tsang A, Wyatt H, Ting N, Beattie T . hTERT mutations associated with idiopathic pulmonary fibrosis affect telomerase activity, telomere length, and cell growth by distinct mechanisms. Aging Cell. 2012; 11(3):482-90. DOI: 10.1111/j.1474-9726.2012.00810.x. View

11.

Wong C, Smith C, Sakamoto K, Kaminski N, Koff J, Goldstein D . Aging Impairs Alveolar Macrophage Phagocytosis and Increases Influenza-Induced Mortality in Mice. J Immunol. 2017; 199(3):1060-1068. PMC: 5557035. DOI: 10.4049/jimmunol.1700397. View

12.

Munoz-Lorente M, Martinez P, Tejera A, Whittemore K, Moises-Silva A, Bosch F . AAV9-mediated telomerase activation does not accelerate tumorigenesis in the context of oncogenic K-Ras-induced lung cancer. PLoS Genet. 2018; 14(8):e1007562. PMC: 6095492. DOI: 10.1371/journal.pgen.1007562. View

13.

Takai H, Smogorzewska A, de Lange T . DNA damage foci at dysfunctional telomeres. Curr Biol. 2003; 13(17):1549-56. DOI: 10.1016/s0960-9822(03)00542-6. View

14.

Plantier L, Crestani B, Wert S, Dehoux M, Zweytick B, Guenther A . Ectopic respiratory epithelial cell differentiation in bronchiolised distal airspaces in idiopathic pulmonary fibrosis. Thorax. 2011; 66(8):651-7. DOI: 10.1136/thx.2010.151555. View

15.

Foust K, Nurre E, Montgomery C, Hernandez A, Chan C, Kaspar B . Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol. 2008; 27(1):59-65. PMC: 2895694. DOI: 10.1038/nbt.1515. View

16.

Stanley S, Chen J, Podlevsky J, Alder J, Hansel N, Mathias R . Telomerase mutations in smokers with severe emphysema. J Clin Invest. 2015; 125(2):563-70. PMC: 4319417. DOI: 10.1172/JCI78554. View

17.

Giangreco A, Reynolds S, Stripp B . Terminal bronchioles harbor a unique airway stem cell population that localizes to the bronchoalveolar duct junction. Am J Pathol. 2002; 161(1):173-82. PMC: 1850682. DOI: 10.1016/S0002-9440(10)64169-7. View

18.

Liu G, Zhai H, Zhang T, Li S, Li N, Chen J . New therapeutic strategies for IPF: Based on the "phagocytosis-secretion-immunization" network regulation mechanism of pulmonary macrophages. Biomed Pharmacother. 2019; 118:109230. DOI: 10.1016/j.biopha.2019.109230. View

19.

King Jr T, Bradford W, Castro-Bernardini S, Fagan E, Glaspole I, Glassberg M . A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014; 370(22):2083-92. DOI: 10.1056/NEJMoa1402582. View

20.

Liu T, Chung M, Ullenbruch M, Yu H, Jin H, Hu B . Telomerase activity is required for bleomycin-induced pulmonary fibrosis in mice. J Clin Invest. 2007; 117(12):3800-9. PMC: 2075478. DOI: 10.1172/JCI32369. View